The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae accommodating a volume of 1 ml of Mueller-Hinton broth (Difco Laboratories) were utilized. Each test isolate was grown overnight on sheep blood agar; then an inoculum of 5 x 105 CFU/ml was prepared by suspending growth to a predetermined optical density. Viable cell counts were performed with each test to verify the actual inoculum density which'was later utilized for MBC determinations. The cuvettes were immediately placed in an MS-2 analysis module and incubated at 35.5°C for 16 h with constant agitation. Optical density-versus-time plots were programmatically derived by the MS-2 system for each bacterial strain and antibiotic. The MIC was defined as the lowest concentration of drug which yielded consistent growth inhibition during the test period as evidenced by review of the kinetic plots. MBCs were determined at the conclusion of the incubation period by removing two 0.1-ml samples from each cuvette well demonstrating growth inhibition and spreading the samples over the entire surface of duplicate Trypticase soy agar (BBL Microbiology Systems) plates. Resultant colonies were counted after 18 to 20 h of incubation at 35°C. The MBC was defined as the lowest concentration of antibiotic resulting in a 23-log decrease in the number of viable organisms (99.9% kill) based on the previously determined inoculum density for each test.
The in vitro synergistic activity of aztreonam in combination with piperacillin, moxalactam, cefotaxime, cefoperazone, and amikacin was examined against multiply resistant isolates of the family Enterobacteriaceae and Pseudomonas aeruginosa. Aztreonam in combination with amikacin demonstrated synergy against 71% of the isolates, whereas combinations of aztreonam plus a second beta-lactam demonstrated synergy against 42% of the isolates.
Empirical therapy of suspected infections in neutropenic patients often consists of antibiotic combinations: usually an antipseudomonal penicillin with an aminoglycoside or possibly a cephalosporin with an aminoglycoside, especially if increased coverage of gram-positive organisms is desired. The rationale for this approach has been the need not only to provide broad-spectrum coverage of potential pathogens, but also to exploit the potentially synergistic action of two antibiotics as opposed to one in the therapy of gram-negative bacteremia (1, 3) .
Aztreonam is a new synthetic beta-lactam antimicrobial agent which belongs to the family of monobactams (8) . It has a high degree of beta-lactamase stability and excellent activity against aerobic gram-negative bacteria (5, 8) . Aztreonam has previously demonstrated synergy when used in combination with gentamicin against certain strains of Pseudomonas aeruginosa and Klebsiella species (9) . More accommodating a volume of 1 ml of Mueller-Hinton broth (Difco Laboratories) were utilized. Each test isolate was grown overnight on sheep blood agar; then an inoculum of 5
x 105 CFU/ml was prepared by suspending growth to a predetermined optical density. Viable cell counts were performed with each test to verify the actual inoculum density which'was later utilized for MBC determinations. The cuvettes were immediately placed in an MS-2 analysis module and incubated at 35.5°C for 16 h with constant agitation. Optical density-versus-time plots were programmatically derived by the MS-2 system for each bacterial strain and antibiotic. The MIC was defined as the lowest concentration of drug which yielded consistent growth inhibition during the test period as evidenced by review of the kinetic plots. MBCs were determined at the conclusion of the incubation period by removing two 0.1-ml samples from each cuvette well demonstrating growth inhibition and spreading the samples over the entire surface of duplicate Trypticase soy agar (BBL Microbiology Systems) plates. Resultant colonies were counted after 18 to 20 h of incubation at 35°C. The MBC was defined as the lowest concentration of antibiotic resulting in a 23-log decrease in the number of viable organisms (99.9% kill) based on the previously determined inoculum density for each test.
To determine possible synergistic effects, the separate MICs for each drug tested separately were combined in MS-2 research cuvettes as follows: 1/8 MIC, 1/4 MIC, 1/2 MIC, MIC, 2 x MIC, 4 x MIC, and 8 x MIC. Inocula and test conditions were the same as described above for testing of drugs separately. Kinetic inhibition curves were examined, and MBCs were also determined as described above. As previously noted by Hallander et al. (2) , synergistic or indifferent outcomes based upon inhibitory criteria were not necessarily predictive of the killing effects of the drug combinations; e.g., a synergistic effect based on MIC criteria Antagonism was not observed with any combination based on MIC determinations, but was seen with three combinations based on MBC results (Table 2) . Two instances involved aztreonam with moxalactam against K. pneumoniae 9 and P. aeruginosa 21. The latter organism was also associated with antagonism involving aztreonam and piperacillin.
The results of this investigation are encouraging with respect to potential clinical applications of combined therapy with aztreonam plus either an aminoglycoside or another beta-lactam antibiotic. However, this effect could not be predicted entirely by knowledge of the species involved, nor was any particular aztreonam-beta-lactam combination more likely to provide a synergistic effect. Certain previous studies have likewise demonstrated variable in vitro synergy results with other new beta-lactams (4, 6, 7), even including strain-and test-method-dependent variation with P. aeruginosa (10) . Thus, animal model or clinical studies will be required to clarify the importance of these observations.
